Leukemia research最新文献

英文中文

Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study 基因预测的 731 种免疫细胞表型在慢性淋巴白血病中的因果作用：一项双向孟德尔随机化研究。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-11-09 DOI: 10.1016/j.leukres.2024.107621

Suying Qian, Jiali Gong, Xiu Shen, Mengjie Chen, Yiquan Cheng, Jingwen Zhu, Mengmeng Huang, Zhilong Shi, Gangfeng Xiao, Keyue Hu, Kesang Li

Introduction

The direct causal relationship between these anomalies and chronic lymphatic leukemia (CLL) remains ambiguous. This study sought to investigate the potential causal link between immune cells and CLL.

Materials and methods

The summary data for genome-wide association studies utilized in this research were sourced from various publicly accessible databases, including the GWAS and FinnGen databases. By amalgamating these extensive genetic resources, we applied an array of cutting-edge Mendelian randomization (MR) analytical techniques. Specifically, we employed the inverse variance weighting (IVW) method, the weighted median method, the MR-Egger method, the Cochran Q test, Leave-One-Out sensitivity analysis, and the weighted model method to rigorously evaluate the potential causal link between multiple immune cell phenotypes and CLL.

Results

IVW analyses consistently demonstrated significant causal associations between five groups of immune cells and CLL. These associations were observed in both forward MR analyses from immune cells to CLL, and reverse MR analyses from CLL to immune cells. The five groups of immune cells under investigation included CD14+ CD16- monocyte Absolute Count, CD4+CD8+ T cell Absolute Count, BAFF-R on IgD- CD27- B cell, HLA DR+ T cell Absolute Count, and CD4+ T cell Absolute Count. Further sensitivity analyses not only confirmed the consistency in the direction of the association but also ruled out potential heterogeneity and horizontal pleiotropy effects. This enhanced the robustness and reliability of the study findings.

Conclusion

This investigation discerned definitive causal links between five immune cell phenotypes and CLL, underscoring the pivotal role of immune cells in the pathogenesis of this disease.

导言：免疫细胞异常与慢性淋巴性白血病（CLL）之间的直接因果关系仍不明确。本研究试图调查免疫细胞与 CLL 之间的潜在因果关系：本研究使用的全基因组关联研究的摘要数据来自各种可公开访问的数据库，包括 GWAS 和 FinnGen 数据库。通过整合这些广泛的基因资源，我们应用了一系列尖端的孟德尔随机化（MR）分析技术。具体来说，我们采用了反方差加权（IVW）法、加权中位数法、MR-Egger 法、Cochran Q 检验、留空敏感性分析和加权模型法，以严格评估多种免疫细胞表型与 CLL 之间的潜在因果联系：IVW分析一致表明，五组免疫细胞与CLL之间存在显著的因果关系。从免疫细胞到 CLL 的正向 MR 分析和从 CLL 到免疫细胞的反向 MR 分析都观察到了这些关联。研究的五组免疫细胞包括 CD14+ CD16- 单核细胞绝对计数、CD4+CD8+ T 细胞绝对计数、IgD- CD27- B 细胞上的 BAFF-R、HLA DR+ T 细胞绝对计数和 CD4+ T 细胞绝对计数。进一步的敏感性分析不仅证实了关联方向的一致性，还排除了潜在的异质性和水平褶积效应。这增强了研究结果的稳健性和可靠性：这项研究发现了五种免疫细胞表型与 CLL 之间的明确因果关系，强调了免疫细胞在该疾病发病机制中的关键作用。

{"title":"Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study","authors":"Suying Qian, Jiali Gong, Xiu Shen, Mengjie Chen, Yiquan Cheng, Jingwen Zhu, Mengmeng Huang, Zhilong Shi, Gangfeng Xiao, Keyue Hu, Kesang Li","doi":"10.1016/j.leukres.2024.107621","DOIUrl":"10.1016/j.leukres.2024.107621","url":null,"abstract":"<div><h3>Introduction</h3><div>The direct causal relationship between these anomalies and chronic lymphatic leukemia (CLL) remains ambiguous. This study sought to investigate the potential causal link between immune cells and CLL.</div></div><div><h3>Materials and methods</h3><div>The summary data for genome-wide association studies utilized in this research were sourced from various publicly accessible databases, including the GWAS and FinnGen databases. By amalgamating these extensive genetic resources, we applied an array of cutting-edge Mendelian randomization (MR) analytical techniques. Specifically, we employed the inverse variance weighting (IVW) method, the weighted median method, the MR-Egger method, the Cochran Q test, Leave-One-Out sensitivity analysis, and the weighted model method to rigorously evaluate the potential causal link between multiple immune cell phenotypes and CLL.</div></div><div><h3>Results</h3><div>IVW analyses consistently demonstrated significant causal associations between five groups of immune cells and CLL. These associations were observed in both forward MR analyses from immune cells to CLL, and reverse MR analyses from CLL to immune cells. The five groups of immune cells under investigation included CD14+ CD16- monocyte Absolute Count, CD4+CD8+ T cell Absolute Count, BAFF-R on IgD- CD27- B cell, HLA DR+ T cell Absolute Count, and CD4+ T cell Absolute Count. Further sensitivity analyses not only confirmed the consistency in the direction of the association but also ruled out potential heterogeneity and horizontal pleiotropy effects. This enhanced the robustness and reliability of the study findings.</div></div><div><h3>Conclusion</h3><div>This investigation discerned definitive causal links between five immune cell phenotypes and CLL, underscoring the pivotal role of immune cells in the pathogenesis of this disease.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107621"},"PeriodicalIF":2.1,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience 同种异体干细胞移植成人和儿童受者中的 COVID-19 感染：英国的经验。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-11-08 DOI: 10.1016/j.leukres.2024.107618

Giovanna Lucchini, Elena Cozma, Aimee Jackson, Kimberly Gilmour, Rachel Protheroe, Keith Wilson, Karl Peggs, Victoria Potter, Anne Parker, Andy Peniket, Eleni Tholouli, Robert Wynn, Emma Nicholson, Charles Craddock, David I. Marks, Christopher Parrish, Shankara Paneesha, Oana Mirci-Danicar, Alexander M. Martin, Graham McIlroy, Persis J. Amrolia

引用次数: 0

Diagnostic challenges and criteria application in a 70-year-old patient with oligo monocytic chronic granulomonocytic leukemia: A case report 一名 70 岁寡单核细胞慢性粒单核细胞白血病患者的诊断难题和标准应用：病例报告。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-11-08 DOI: 10.1016/j.leukres.2024.107616

Xiaomei Wang, Tao Chen

引用次数: 0

Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvement: Insights from a single center 噻替帕-布磺安-氟达拉滨调理法是治疗髓外受累血液恶性肿瘤的单倍体同种异体造血干细胞移植前的有效方法：来自单一中心的启示。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-11-07 DOI: 10.1016/j.leukres.2024.107617

Xianbo Huang , Xianhui Wu , Shasha Wang , Yanling Ren , Yu Xu , Chen Mei , Jie Jin , Hongyan Tong , Jiejing Qian

引用次数: 0

Causes of death in patients with myelodysplastic syndrome and spliceosome mutations 骨髓增生异常综合征和剪接体突变患者的死亡原因。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-11-06 DOI: 10.1016/j.leukres.2024.107612

Panayiotis D. Kontoyiannis , Arjun S. Peddireddy , Koji Sasaki, Kelly Chien, Jayastu Senapati, Guillermo Montalban-Bravo, Courtney DiNardo, Gautam Borthakur, Rashmi Kanagal-Shamanna, Carlos Bueso-Ramos, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Samuel Urrutia

引用次数: 0

Advances in the treatment of mantle cell lymphoma with BTK inhibitors 用 BTK 抑制剂治疗套细胞淋巴瘤的进展。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-11-05 DOI: 10.1016/j.leukres.2024.107615

Jiwei Shen , Jiawei Li , Rui Yang , Shuang Wu , Zhimei Mu , Shi Ding , Xinyu Zhang , Meiying Duo , Ye Chen , Ju Liu

Mantle cell lymphoma (MCL) is a heterogenous disease that is one of the most challenging blood cancers due to its poor prognosis, high risk of relapse and drug resistance. Recent researches have brought significant changes in MCL patients outcomes and new clinical. Bruton's Tyrosine Kinase (BTK), a key kinase in the B-cell antigen receptor (BCR) signaling pathway, is a clinical research hot spot and plays a major role in the survival and spread of malignant B cells. The first generation of BTK inhibitors, led by ibrutinib, have shown promising results in targeted treatment. Meanwhile, several inhibitors have entered clinical studies and demonstrated outstanding therapeutic activity in clinical trials for MCL, indicating a good prospect for development. Despite these encouraging findings, the duration of response is limited, and resistance to BTK inhibitors develops in a portion of individuals. This review summarizes the pathogenesis of MCL and targeted BTK inhibitors and provides an overview of the mutations that can lead to resistance to BTK inhibitors. The purpose of this article is to review the literature describing these selective therapies and provides perspectives for their further development.

套细胞淋巴瘤（MCL）是一种异质性疾病，因其预后差、复发风险高和耐药性强而成为最具挑战性的血液癌症之一。最近的研究为 MCL 患者的预后带来了重大变化，也带来了新的临床方法。布鲁顿酪氨酸激酶（BTK）是B细胞抗原受体（BCR）信号通路中的一个关键激酶，是临床研究的热点，在恶性B细胞的存活和扩散中发挥着重要作用。以伊布替尼（ibrutinib）为首的第一代 BTK 抑制剂在靶向治疗方面取得了可喜的成果。同时，一些抑制剂已进入临床研究，并在 MCL 的临床试验中表现出突出的治疗活性，显示出良好的发展前景。尽管这些研究结果令人鼓舞，但反应持续时间有限，部分患者会对 BTK 抑制剂产生耐药性。这篇综述总结了 MCL 和 BTK 靶向抑制剂的发病机制，并概述了可能导致对 BTK 抑制剂产生耐药性的突变。本文旨在回顾描述这些选择性疗法的文献，并为这些疗法的进一步发展提供展望。

{"title":"Advances in the treatment of mantle cell lymphoma with BTK inhibitors","authors":"Jiwei Shen , Jiawei Li , Rui Yang , Shuang Wu , Zhimei Mu , Shi Ding , Xinyu Zhang , Meiying Duo , Ye Chen , Ju Liu","doi":"10.1016/j.leukres.2024.107615","DOIUrl":"10.1016/j.leukres.2024.107615","url":null,"abstract":"<div><div>Mantle cell lymphoma (MCL) is a heterogenous disease that is one of the most challenging blood cancers due to its poor prognosis, high risk of relapse and drug resistance. Recent researches have brought significant changes in MCL patients outcomes and new clinical. Bruton's Tyrosine Kinase (BTK), a key kinase in the B-cell antigen receptor (BCR) signaling pathway, is a clinical research hot spot and plays a major role in the survival and spread of malignant B cells. The first generation of BTK inhibitors, led by ibrutinib, have shown promising results in targeted treatment. Meanwhile, several inhibitors have entered clinical studies and demonstrated outstanding therapeutic activity in clinical trials for MCL, indicating a good prospect for development. Despite these encouraging findings, the duration of response is limited, and resistance to BTK inhibitors develops in a portion of individuals. This review summarizes the pathogenesis of MCL and targeted BTK inhibitors and provides an overview of the mutations that can lead to resistance to BTK inhibitors. The purpose of this article is to review the literature describing these selective therapies and provides perspectives for their further development.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107615"},"PeriodicalIF":2.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population 类固醇难治性急性/慢性移植物抗宿主疾病的治疗：在高风险人群中使用鲁索利替尼联合体外射频消融术的单中心实际经验

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-29 DOI: 10.1016/j.leukres.2024.107611

V. Wais, A. Gantner, K. Strauss, A. Neagoie, C. Weidt, J. Schnell, H. Döhner, D. Bunjes, E. Sala

Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT). The JAK1/2-inhibitor ruxolitinib and the extracorporeal photopheresis (ECP) have been shown to significantly improve the overall response rate (ORR) in this setting. However, about 30–40 % of high-risk patients do not respond to monotherapy and/or experience side effects. Considering the potential synergic mechanism of action of ruxolitinib and ECP and the good safety profile, we decided to investigate the role of a treatment strategy of ruxolitinib in combination with ECP in frail patients with high-risk SR-a/cGvHD. We conducted a retrospective single-center study comprising 47 patients who underwent allo-SCT from November 2018 to October 2023 and received treatment for SR-aGvHD (n=20) or SR-cGvHD (n=27) with ruxolitinib and ECP. In the SR-aGvHD group, 95 % of patients had a lower GI-tract involvement, with 80 % presenting with a grade III-IV SR-aGvHD. The ORR at day +28 was 65 %, with a 30 % CR rate. The 1-year overall survival (OS) for responders (PR and CR) was 33 % (95 % CI, 10 %-59 %). In the SR-cGvHD group, 55.6 % and 44.4 % had moderate and severe SR-cGvHD, respectively. The majority of patients (66.7 %) had a GI-involvement. The ORR at week 24 was 88 %, including 12 % CR and 76 % PR. The 1-year OS for responders was 76 % (95 % CI, 47 %-90 %). Our retrospective analysis shows that the treatment of ruxolitinib in combination with ECP has potential efficacy in patients with SR-a/cGvHD with a high-risk for transplantation-associated mortality.

类固醇难治性急性和慢性移植物抗宿主疾病（SR-a/cGvHD）是异基因干细胞移植（allo-SCT）后可能危及生命的并发症。在这种情况下，JAK1/2抑制剂鲁索利替尼（ruxolitinib）和体外光化疗法（ECP）已被证明可显著提高总反应率（ORR）。然而，约30%-40%的高危患者对单药治疗无反应和/或出现副作用。考虑到Ruxolitinib和ECP潜在的协同作用机制以及良好的安全性，我们决定研究Ruxolitinib联合ECP的治疗策略在体弱的SR-a/cGvHD高危患者中的作用。我们开展了一项回顾性单中心研究，研究对象包括2018年11月至2023年10月接受allo-SCT的47例患者，他们接受了鲁索利替尼和ECP治疗SR-aGvHD（n=20）或SR-cGvHD（n=27）。在SR-aGvHD组中，95%的患者下消化道受累，80%的患者出现III-IV级SR-aGvHD。第28天的ORR为65%，CR为30%。应答者（PR和CR）的1年总生存率（OS）为33%（95% CI，10%-59%）。在 SR-cGvHD 组中，中度和重度 SR-cGvHD 分别占 55.6% 和 44.4%。大多数患者（66.7%）有消化道受累。第24周的ORR为88%，包括12%的CR和76%的PR。应答者的 1 年 OS 为 76%（95% CI，47%-90%）。我们的回顾性分析表明，对于具有移植相关死亡率高风险的SR-a/cGvHD患者，鲁索利替尼联合ECP治疗具有潜在疗效。

{"title":"Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population","authors":"V. Wais, A. Gantner, K. Strauss, A. Neagoie, C. Weidt, J. Schnell, H. Döhner, D. Bunjes, E. Sala","doi":"10.1016/j.leukres.2024.107611","DOIUrl":"10.1016/j.leukres.2024.107611","url":null,"abstract":"<div><div>Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT). The JAK1/2-inhibitor ruxolitinib and the extracorporeal photopheresis (ECP) have been shown to significantly improve the overall response rate (ORR) in this setting. However, about 30–40 % of high-risk patients do not respond to monotherapy and/or experience side effects. Considering the potential synergic mechanism of action of ruxolitinib and ECP and the good safety profile, we decided to investigate the role of a treatment strategy of ruxolitinib in combination with ECP in frail patients with high-risk SR-a/cGvHD. We conducted a retrospective single-center study comprising 47 patients who underwent allo-SCT from November 2018 to October 2023 and received treatment for SR-aGvHD (n=20) or SR-cGvHD (n=27) with ruxolitinib and ECP. In the SR-aGvHD group, 95 % of patients had a lower GI-tract involvement, with 80 % presenting with a grade III-IV SR-aGvHD. The ORR at day +28 was 65 %, with a 30 % CR rate. The 1-year overall survival (OS) for responders (PR and CR) was 33 % (95 % CI, 10 %-59 %). In the SR-cGvHD group, 55.6 % and 44.4 % had moderate and severe SR-cGvHD, respectively. The majority of patients (66.7 %) had a GI-involvement. The ORR at week 24 was 88 %, including 12 % CR and 76 % PR. The 1-year OS for responders was 76 % (95 % CI, 47 %-90 %). Our retrospective analysis shows that the treatment of ruxolitinib in combination with ECP has potential efficacy in patients with SR-a/cGvHD with a high-risk for transplantation-associated mortality.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107611"},"PeriodicalIF":2.1,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142579064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review 皮肤黑色素瘤与血液系统恶性肿瘤并发的流行病学和遗传学研究：荟萃分析综述。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-26 DOI: 10.1016/j.leukres.2024.107610

Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan

Background

The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).

Aim

This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.

Methodology

A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.

The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).

Results

Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.

Conclusion

This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.

背景：近年来，由于早期诊断的进步和生存期的延长，癌症幸存者的人数不断增加。现有文献表明，皮肤黑色素瘤（CM）与血液系统恶性肿瘤（HM）之间存在联系。研究目的：本研究旨在审查关于皮肤黑色素瘤与血液系统恶性肿瘤之间联系的流行病学研究，并探讨导致这种联系的遗传、生物和环境因素：方法：进行文献综述和荟萃分析，评估 HM 后患 CM 的风险，反之亦然。纳入研究的数据均报告了标准化发病率比（SIR）或危险比（HR）及95%置信区间（CI），研究采用随机效应模型对这些数据进行了汇总。使用 I² 和 Cochrane Q 检验统计量评估研究之间的异质性。采用随机效应模型对发病率数据进行了汇总。本综述已在 PROSPERO（CRD42022359887）上注册：10项研究的重点是CM患者的HM诊断，包括189094人的合并队列，11项研究的重点是HM患者的CM诊断，包括306967人的队列。CM 后 HM 的 SIR 在 1.25 到 3.12 之间，而 HM 后 CM 的 SIR 在 0.83 到 4.12 之间。合并 CM 患者中 HM 的比例为 62.4%，合并 HM 患者中 CM 的比例为 19.6%。统计异质性很高，I²值分别为99.19%和89.15%：本综述证实了同一患者的 CM 和 HM 之间存在关联。这种关联主要归因于涉及 BRAF-V600K、酪氨酸激酶通路基因、CDKN2A (P16) 和 BCL-2 的遗传因素。此外，紫外线辐射和免疫功能受损等风险因素也与这些癌症的发病率有关。

{"title":"Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review","authors":"Ashmitha Kumar, Arunan Jeyakumar, Alfred K. Lam, Vinod Gopalan","doi":"10.1016/j.leukres.2024.107610","DOIUrl":"10.1016/j.leukres.2024.107610","url":null,"abstract":"<div><h3>Background</h3><div>The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).</div></div><div><h3>Aim</h3><div>This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.</div></div><div><h3>Methodology</h3><div>A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.</div><div>The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).</div></div><div><h3>Results</h3><div>Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.</div></div><div><h3>Conclusion</h3><div>This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107610"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology 利用微细胞技术对原发性多发性骨髓瘤细胞的药物反应进行体外测试

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-26 DOI: 10.1016/j.leukres.2024.107599

Josefine Krüger , Igor Wolfgang Blau , Olga Blau , Alice Bettelli , Laura Rocchi , Massimo Bocchi , Jan Krönke , Lars Bullinger , Ulrich Keller , Axel Nogai

Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of in vitro drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and in vitro drug response of primary myeloma cells was analyzed. In vitro responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability in vitro. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy in vitro. To further validate these in vitro results against in vivo outcomes, screening a larger cohort is necessary.

多发性骨髓瘤是一种浆细胞侵袭性肿瘤。虽然许多药物已获得批准，但缺乏针对个体药物反应的既定预测指标构成了挑战。在这项研究中，我们探索了基于微波和荧光的 Cellply CC-Array® 技术，该技术可用于体外药物反应的高通量分析，是患者治疗效果的潜在预测标志物。此外，我们还研究了该技术在评估效应细胞有效性方面的应用。我们从 22 名患者的骨髓中分离出单核细胞，分析了原发性骨髓瘤细胞的体外药物反应。原代患者样本对美法仑、硼替佐米和地塞米松的体外反应与患者的临床反应相关。由于骨髓瘤体外存活率低导致培养时间有限，这种方法在确定对来那度胺、达拉曲单抗和艾洛妥珠单抗的敏感性方面存在局限性。通过分析细胞接近性，该平台能够评估 NK 和 T 细胞的个体抗肿瘤活性。总之，CC-Array 微阵列技术可以在体外评估骨髓瘤细胞对用于多发性骨髓瘤治疗的特定药物的反应。为了进一步验证这些体外结果与体内结果的一致性，有必要对更大的群体进行筛选。

{"title":"In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology","authors":"Josefine Krüger , Igor Wolfgang Blau , Olga Blau , Alice Bettelli , Laura Rocchi , Massimo Bocchi , Jan Krönke , Lars Bullinger , Ulrich Keller , Axel Nogai","doi":"10.1016/j.leukres.2024.107599","DOIUrl":"10.1016/j.leukres.2024.107599","url":null,"abstract":"<div><div>Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of <em>in vitro</em> drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and <em>in vitro</em> drug response of primary myeloma cells was analyzed. <em>In vitro</em> responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability <em>in vitro</em>. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy <em>in vitro</em>. To further validate these <em>in vitro</em> results against <em>in vivo</em> outcomes, screening a larger cohort is necessary.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107599"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis 体重指数对慢性白血病患者服用博舒替尼安全性的影响：事后汇总数据分析。

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research

Pub Date : 2024-10-24 DOI: 10.1016/j.leukres.2024.107609

Susanne Isfort, Carlo Gambacorti-Passerini, Tim H. Brümmendorf, B. Douglas Smith, Simon Purcell, Maja Strecker, Huadong Zhao, Luke Kuttschreuter, Jane Apperley

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Leukemia research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀